Restoring long-lasting midface volume in the Asian face with a hyaluronic acid filler : A randomized controlled multicenter study
© 2024 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC..
BACKGROUND: Hyaluronic acid (HA) filler treatment is a minimally-invasive alternative to surgery to volumize the cheeks. HAVOL (Restylane® Volyme) is a flexible HA filler suited to contouring and volumizing the midface.
METHODS: This randomized, evaluator-blinded, no-treatment controlled study evaluated effectiveness and safety of HAVOL for correction of midface volume deficit and midface contour deficiency in Chinese subjects. In total 111 subjects were randomized to HAVOL and 37 to no treatment (control). The primary endpoint was response, on the blinded evaluator-assessed Medicis Midface Volume Scale (MMVS), at 6 months after last injection for the treatment group and 6 months after randomization for controls, where response was defined as ≥1-point improvement from baseline on both sides of the face.
RESULTS: HAVOL was superior to no treatment at 6 months, meeting the primary objective: 76% versus 8% MMVS responders, a difference of 68% (CI: 55.7%-79.4%, p < 0.0001). These effects were sustained in 51% at 12 months after last injection. A majority (≥96%) had improved aesthetic appearance of midface fullness at Month 1 (using the Global Aesthetic Improvement Scale [GAIS]), effects which remained in ≥80% up to 12 months. Volume change captured by 3D photography increased after 1 month to 3.6 mL (close to the total injected volume of 3.4 mL), and remained stable through 12 months. Over 97% reported satisfaction with results after treatment with HAVOL . Additionally, HAVOL was well tolerated, with no unanticipated related adverse events.
CONCLUSIONS: This study showed that HAVOL is effective and well tolerated for midface treatment in a Chinese population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of cosmetic dermatology - (2024) vom: 15. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ren, Rongxin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chinese |
|---|
| Anmerkungen: |
Date Revised 15.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1111/jocd.16221 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369776445 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369776445 | ||
| 003 | DE-627 | ||
| 005 | 20240315234807.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jocd.16221 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1331.xml |
| 035 | |a (DE-627)NLM369776445 | ||
| 035 | |a (NLM)38487954 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ren, Rongxin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Restoring long-lasting midface volume in the Asian face with a hyaluronic acid filler |b A randomized controlled multicenter study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: Hyaluronic acid (HA) filler treatment is a minimally-invasive alternative to surgery to volumize the cheeks. HAVOL (Restylane® Volyme) is a flexible HA filler suited to contouring and volumizing the midface | ||
| 520 | |a METHODS: This randomized, evaluator-blinded, no-treatment controlled study evaluated effectiveness and safety of HAVOL for correction of midface volume deficit and midface contour deficiency in Chinese subjects. In total 111 subjects were randomized to HAVOL and 37 to no treatment (control). The primary endpoint was response, on the blinded evaluator-assessed Medicis Midface Volume Scale (MMVS), at 6 months after last injection for the treatment group and 6 months after randomization for controls, where response was defined as ≥1-point improvement from baseline on both sides of the face | ||
| 520 | |a RESULTS: HAVOL was superior to no treatment at 6 months, meeting the primary objective: 76% versus 8% MMVS responders, a difference of 68% (CI: 55.7%-79.4%, p < 0.0001). These effects were sustained in 51% at 12 months after last injection. A majority (≥96%) had improved aesthetic appearance of midface fullness at Month 1 (using the Global Aesthetic Improvement Scale [GAIS]), effects which remained in ≥80% up to 12 months. Volume change captured by 3D photography increased after 1 month to 3.6 mL (close to the total injected volume of 3.4 mL), and remained stable through 12 months. Over 97% reported satisfaction with results after treatment with HAVOL . Additionally, HAVOL was well tolerated, with no unanticipated related adverse events | ||
| 520 | |a CONCLUSIONS: This study showed that HAVOL is effective and well tolerated for midface treatment in a Chinese population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chinese | |
| 650 | 4 | |a fillers | |
| 650 | 4 | |a hyaluronic acid | |
| 650 | 4 | |a midface | |
| 650 | 4 | |a randomized controlled study | |
| 700 | 1 | |a Xue, Hongyu |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Zhanwei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hang |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Xiujuan |e verfasserin |4 aut | |
| 700 | 1 | |a Qu, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Bromée, Torun |e verfasserin |4 aut | |
| 700 | 1 | |a Almegård, Birgitta |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Hongyi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cosmetic dermatology |d 2002 |g (2024) vom: 15. März |w (DE-627)NLM166816639 |x 1473-2165 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jocd.16221 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 03 | ||